我们测试了针对已完成手术、化疗和放疗（允许持续内分泌治疗）的早期乳腺癌女性的在线饮食和身体活动计划的可行性和初步疗效。水果和蔬菜 (F/V) 摄入量较低和/或中度至剧烈体力活动 (MVPA) 水平较低的参与者被随机分配到两种剂量之一：低剂量（1 次 Zoom 组疗程）或高剂量（12 次 Zoom 组疗程） - 旨在提高 F/V 摄入量和 MVPA 的在线生活方式计划。所有参与者都收到了电子健康通讯（短信、研究网站访问）、Fitbit 和支持 WiFi 的体重秤。主要目标评估可行性。次要目标比较两个剂量组之间 F/V 摄入量和 MVPA 的 6 个月变化。共有 74 名女性（平均年龄 = 58.4 岁；87% 非西班牙裔白人；自诊断以来的平均时间 = 4.6 年）进行了统计。在低剂量组的女性中，94% 参加了单次治疗；在高剂量组的女性中，84% 的女性至少参加了 12 次治疗中的 8 次。 6 个月时的保留率为 93%。与低剂量参与者相比，高剂量参与者在 6 个月时每天多消耗 1.5 份 F/V (P = 0.007)，但组间 MVPA 水平没有差异。我们成功地为早期乳腺癌幸存者实施了在线生活方式计划。高剂量干预在改善早期乳腺癌幸存者的 F/V 消耗方面显示出初步功效。未来的试验可以在更大、更多样化的乳腺癌幸存者群体中测试干预措施。© 2024。作者。

We tested the feasibility and preliminary efficacy of an online diet and physical activity program for women with early-stage breast cancer who had completed surgery, chemotherapy, and radiation therapy (ongoing endocrine therapy allowed). Participants with low fruit and vegetable (F/V) consumption and/or low moderate-to-vigorous physical activity (MVPA) levels were randomized to one of two doses - low (one Zoom group session) or high (12 Zoom group sessions) - of an online lifestyle program with the goal of improving F/V intake and MVPA. All participants received eHealth communications (text messages, study website access), a Fitbit, and a WiFi-enabled scale. Primary objectives evaluated feasibility. Secondary objectives compared the 6-month change in F/V intake and MVPA between the two dose groups. Seventy-four women (mean age = 58.4 years; 87% non-Hispanic White; mean time since diagnosis = 4.6 years) were accrued. Among women in the low dose group, 94% attended the single session; among women in the high dose group, 84% attended at least 8 of the 12 sessions. Retention at 6 months was 93%. High relative to low dose participants consumed 1.5 more servings/day of F/V at 6 months (P = 0.007) but MVPA levels did not differ between groups. We successfully implemented an online lifestyle program for early-stage breast cancer survivors. The high dose intervention demonstrated preliminary efficacy in improving F/V consumption in early-stage breast cancer survivors. Future trials can test the intervention in a larger and more diverse population of breast cancer survivors.© 2024. The Author(s).